Posted On: 01/13/2015 9:58:30 PM
Post# of 30066
Not sure what some people think the company is doing at an investor conference. Selling snow cones?
It's pretty simple. By going and presenting at these:
Jan. 13, 2015 - Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Jan. 8, 2015 - Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
Dec. 29, 2014 - Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
You raise awareness on the work you are doing, ODD, smart acquisitions, etc. which previously was going under the radar. Examples:
Dec. 23, 2014 - Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Jan. 12, 2015 - Amarantus BioSciences, Inc. Announces Acquisition Of Specialized Neuro-Diagnostics Company, DioGenix
Nov. 17, 2014 - Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Which in turn gets people wanting to invest and price & volume go up.
It's pretty simple. By going and presenting at these:
Jan. 13, 2015 - Amarantus to Present at Noble Financial Capital Markets' Eleventh Annual Investor Conference
Jan. 8, 2015 - Amarantus to Participate in the Eighth Annual OneMedForum Conference on January 12 - 13, 2015
Dec. 29, 2014 - Amarantus to Present LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R) at Biotech Showcase 2015 Conference on January 14, 2015
You raise awareness on the work you are doing, ODD, smart acquisitions, etc. which previously was going under the radar. Examples:
Dec. 23, 2014 - Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
Jan. 12, 2015 - Amarantus BioSciences, Inc. Announces Acquisition Of Specialized Neuro-Diagnostics Company, DioGenix
Nov. 17, 2014 - Amarantus Enters Into Exclusive Option Agreement to Acquire Engineered Skin Substitute for the Treatment of Severe Burns From Lonza
Which in turn gets people wanting to invest and price & volume go up.
(0)
(0)
